print
mail
Home
Media
In the News
Amgen Finalizes ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA
Overview
Fact Sheets
Featured Content
Press Releases
Social Media
Media Contacts
In the News
Virtual Press Kits
ESAs in the News
Amgen Finalizes ESA Risk Evaluation and Mitigation Strategy (REMS) With FDA
ESA REMS – Aranesp®
ESA REMS – EPOGEN®
Nephrology Professional Society Letter
The following tools are for the ESA APPRISE Oncology Program, which will be launched on March 24, 2010.
Dear Healthcare Provider (DHCP) Letter to HCPs who may purchase or prescribe ESAs for patients with cancer
Dear Healthcare Provider (DHCP) Letter to hospital Directors of Pharmacy/Administrators
Oncology related Professional Society Letter
ESA APPRISE Oncology Program Enrollment form for Healthcare Providers
ESA APPRISE Oncology Program Enrollment form for hospitals
ESA APPRISE Oncology Program Patient and Healthcare Professional (HCP) Acknowledgment Form
ESA APPRISE Oncology Program HCP Requirements Flashcard
ESA APPRISE Oncology Program Hospital Process Overview Flashcard
HCP Program Starter Kit
ESA REMS Flashcard
ESA APPRISE Oncology Program Training Module for Hospital Designees
ESA APPRISE Oncology Program Training Module for HCPs
Screenshots for the ESA APPRISE Oncology Program website
Related Links
Products
Pipeline
Corporate Citizenship
Locations
footer
